Press Releases
-
Veranex Announces Acquisition of Experien Group
Veranex, the first concept-to-commercialization global service provider dedicated to the medtech industry, today announced the acquisition of Experien Group, a leading provider of a full range of regulatory, quality, and clinical consulting services to medtech companies.
Aug 2, 2021
-
Panthera steps up its move into oncology trials with more than 12 trials in the pipeline and a prostate trial underway
Many cancer clinical research trials were put on hold during Covid – now Panthera Biopartners and Rutherford Health are working in partnership to accelerate oncology research in order to provide improved care for patients.
Aug 11, 2021
-
ADVANZ PHARMA partners with Ashfield Engage to deliver talent acquisition strategy for European specialty medicine division
Ashfield Engage, part of UDG Healthcare plc, announced that it has partnered with ADVANZ PHARMA to develop and deliver a pan-European talent acquisition programme for ADVANZ PHARMA’s specialty medicine division.
Aug 15, 2021
-
Sensyne Health and Sentara Healthcare Form New Partnership for Ethical Data Sharing and Design of New Clinical Algorithms
-
Combination of Viral Therapy and T Cell Therapy to Improve The Cure Rate of Cancer
-
IntegrateRNA Offers High-quality Oligonucleotide Conjuagted to Facilitate Diagnostic and Targeted Drug Delivery
-
Histobiolab: One-Stop Source for Blood Samples to Support Studying Progress of Disease Processes
-
Noxopharm Pre-clinical Study Confirms Survival Advantage of Combination LuPSMA Therapy in Prostate Cancer
Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) has reported pre-clinical data confirming a survival benefit of adding Veyonda® to 177lutetium-PSMA-617 (LuPSMA) treatment in prostate cancer.
Aug 11, 2021
-
Clinical Ink CBO Jonathan Andrus Selected as DTRA Co-Leader
Clinical Ink, a global clinical trial technology company, today announced that CBO Jonathan Andrus has been selected to co-lead the Decentralized Trials & Research Alliance’s (DTRA) Initiative 4B: Collaborate on Regulatory Gaps.
Aug 11, 2021
-
MicrobioSeq Division Releases Viral Metagenomics Services to Study Viruses
-
Biotium Launches Optimized Solution for Exosome Detection by Flow Cytometry
Biotium Launches Optimized Solution for Exosome Detection by Flow Cytometry
Aug 11, 2021
-
Enveda Biosciences Boosts its Translational Capabilities with Two Key Hires
-
BioIVT Opens New, Larger UK Blood Donor Center on Imperial College London’s White City Campus
BioIVT’s new blood donor center is located in White City, a biotech hub, together with cell therapy, gene therapy, and pharmaceutical companies.
Jul 12, 2021
-
Thermo Fisher Scientific and UC Davis Launch Center of Excellence in Clinical Metabolomics
Thermo Fisher Scientific today announced their collaboration with the UC Davis West Coast Metabolomics Center to form The Center of Excellence in Clinical Metabolomics.
Jul 6, 2021
-
Protheragen MedAI Fully Supports In Vitro Pharmacology Research for Drug Discovery
-
Flywheel and HealthMyne Partner to Provide End-to-End Radiomic Data Management and Analysis
Flywheel and Healthmyne: Combined technology solution to accelerate radiomics research and clinical trial outcomes
Jul 6, 2021
-
CD Formulation Launches a Full Range of Drug Analysis Services for the Pharmaceutical Industry
-
Alfa Chemistry Materials Announces a New Product Offering of Quantum Dots
-
Rho to Coordinate Study Sponsored by NIAID to Assess Systemic Allergic Reactions to Pfizer and Moderna COVID-19 Vaccines
Rho, a full-service contract research organization (CRO) with a proven track record of drug development success, today announced it is coordinating a study called Systemic Allergic Reactions to SARS-CoV-2 Vaccination to assess the proportion of participants with a systemic allergic reaction to the Pfizer-BioNTech and Moderna COVID-19 vaccines in populations at high risk for allergic reaction compared to a general population. This research will be important for further understanding potential risk factors for an allergic reaction to these particular vaccines, as well as to future vaccines that similarly use an mRNA nanoparticle platform. The study is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
Jul 13, 2021
-
AUI and Accumen Partner to Increase Crisis Resilience to Natural and Manmade Disasters for Healthcare Sector
These new programs will ensure that healthcare organizations are better prepared to handle security threats, and power, water/waste management or supply chain disruptions.
Jul 12, 2021